EcoDrugPlus

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSAOCG00000024285
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha-Like

Ensembl ID : ENSAOCG00000009831
Gene Symbol: LOC111571308
3 Cross references
245 Possible Orthologues:

Sodium Channel Protein Type 5 Subunit Alpha-Like

Ensembl ID : ENSAOCG00000024390
Gene Symbol: LOC111575321
3 Cross references
223 Possible Orthologues:

Sodium Channel Protein Type 8 Subunit Alpha-Like

Ensembl ID : ENSAOCG00000006155
Gene Symbol: LOC111588749
2 Cross references
219 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSAOCG00000014317
Gene Symbol: SCN4A
4 Cross references
187 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSAOCG00000013169
Gene Symbol: SCN8A
4 Cross references
218 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSAOCG00000006978
Gene Symbol: LOC111588706
3 Cross references
204 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSAOCG00000020893
Gene Symbol: LOC111565637
2 Cross references
292 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-2-Like

Ensembl ID : ENSAOCG00000012014
Gene Symbol: LOC111574622
3 Cross references
204 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-233-Like

Ensembl ID : ENSAOCG00000014615
Gene Symbol: LOC111568143
3 Cross references
215 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3-Like

Ensembl ID : ENSAOCG00000013438
Gene Symbol: LOC111568840
3 Cross references
230 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSAOCG00000002219
Gene Symbol: SLC10A2
3 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).